The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Ras mediates cell proliferation, survival and differentiation. Mutations in K-Ras4B are predominant at residues G12, G13 and Q61. Even though all impair GAP-assisted GTP → GDP hydrolysis, the mutation frequencies of K-Ras4B in human cancers vary. Here we aim to figure out their mechanisms and differential oncogenicity. In total, we performed 6.4 μs molecular dynamics simulations on the wild-type K-Ras4B (K-Ras4B WT-GTP/GDP) catalytic domain, the K-Ras4B WT-GTP–GAP complex, and the mutants (K-Ras4B G12C/G12D/G12V-GTP/GDP, K-Ras4B G13D-GTP/GDP, K-Ras4B Q61H-GTP/GDP) and their complexes with GAP. In addition, we simulated ‘exchanged’ nucleotide states. These comprehensive simulations reveal that in solution K-Ras4B WT-GTP exists in two, active and inactive, conformations. Oncogenic mutations differentially elicit an inactive-to-active conformational transition in K-Ras4B-GTP; in K-Ras4B G12C/G12D-GDP they expose the bound nucleotide which facilitates the GDP-to-GTP exchange. These mechanisms may help elucidate the differential mutational statistics in K-Ras4B-driven cancers. Exchanged nucleotide simulations reveal that the conformational transition is more accessible in the GTP-to-GDP than in the GDP-to-GTP exchange. Importantly, GAP not only donates its R789 arginine finger, but stabilizes the catalytically-competent conformation and pre-organizes catalytic residue Q61; mutations disturb the R789/Q61 organization, impairing GAP-mediated GTP hydrolysis. Together, our simulations help provide a mechanistic explanation of key mutational events in one of the most oncogenic proteins in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most frequent mutant forms were KRASG12D (41%), KRASG12V (28%), and KRASG12C (14%).49”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutations in G12, G13, or Q61 residue in the active site can lock KRAS in the GTP-bound form by impeding the hydrolysis to GDP catalyzed by GAPs, thus keeping downstream signaling constitutively active [16, 17].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [16]
In the citing paper
“The total simulation times of these studies were in the range of 1–8 μs, which is reasonable but likely not sufficient to unravel long-time dynamics associated with slow conformational changes.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of simple potential functions for simulating liquid water
Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983) · The Journal of Chemical Physics · doi:10.1063/1.445869 · Cited by 41,298
Particle mesh Ewald: An N ⋅log( N ) method for Ewald sums in large systems
Darden, T., York, D., & Pedersen, L. (1993) · The Journal of Chemical Physics · doi:10.1063/1.464397 · Cited by 30,546
Ryckaert, J.-P., Ciccotti, G., & Berendsen, H. J. C. (1977) · Journal of Computational Physics · doi:10.1016/0021-9991(77)90098-5 · Cited by 21,239
The Amber biomolecular simulation programs
Case, D. A., Cheatham, T. E., Darden, T., Gohlke, H., Luo, R., Merz, K. M., Onufriev, A., Simmerling, C., Wang, B., & Woods, R. J. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20290 · Cited by 9,535
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Regulation of Small GTPases by GEFs, GAPs, and GDIs
Cherfils, J., & Zeghouf, M. (2013) · Physiological Reviews · doi:10.1152/physrev.00003.2012 · Cited by 1,245
Cited by
Items 201–225 of 225
Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer
Liu, X., Wu, C., Song, S., Ma, L., Huang, S., He, Y., Li, Q., Chang, Y., Jiang, D., Mei, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.202523795 · Cited by 1
“Mutations in KRAS are predominant at codons 12, 13, and 61 within its GTPase domain, leading to its continuous activation, thereby driving cancer progression [ 12, 13 ].”
Functional differences drive the selection of NRAS mutants in melanomaPreprint
Murphy, B., Weiss, T. J., Holderbaum, A. M., Dhakal, A., Fort, M., Bodnar, M. S., Chen, M., Burd, C. J., Coppola, V., & Burd, C. E. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.15.426808 · Cited by 1
“to variances in GTP binding and hydrolysis (Lu et al. 2016; Novelli et al. 2018).”
BackgroundMarcus (2018) · Digital Repository Service (Northeastern University) · doi:10.17760/d20286915 · Cited by 1
Agosile, O. O., Njoku, P. C., Oduwe, U., Aremu, A. J., Fajobi, S. J., Akachukwu, S. O., Adebisi, A. R., Abolaji, A. O., & Omirin, E. S. (2023) · Research Square · doi:10.21203/rs.3.rs-3079675/v1 · Cited by 1
Mechanistic Insight on Ras Inhibition Strategies in Cancer Therapy
Anoosheh, J. P., Barzegar, A., Hejazi, M. S., Hasheminejad, N., Heidari, H. R., & Aghdam, E. M. (2021) · Pharmaceutical Sciences · doi:10.34172/ps.2021.25
“Having Ras proteins undergone post-translational modifications, the HVR is fused to the cell membrane.(16) H-Ras, K-Ras, and N-Ras are tumor oncoproteins that belong to a larger superfamily of GDP and GTP binding proteins, which hydrolyze GTP into GDP.”
BackgroundAnoosheh, J. P., Barzegar, A., Hejazi, M. S., & Aghdam, E. M. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121053
Lecian, O. M. (2023) · IgMin Research · doi:10.61927/igmin133
“The results interpreted from molecular dynamics simulations might allow one to infer that di ff erent mutants have di ff erent dynamics [19-21] according to the di ff erent Markov landscapes.”
BackgroundConditional Cooperativity in RAS Assembly Pathways on Nanodiscs and Altered GTPase Cycling
Lee, S., & Lee, K. (2024) · Angewandte Chemie · doi:10.1002/ange.202316942 · Cited by 1
Therapeutic Targeting of KRAS Oncogene in Pancreatic Ductal Adenocarcinoma (PDAC)
Song, J. J. (2024) · Journal of Student Research · doi:10.47611/jsrhs.v13i1.6375
PARLAK, S. N. (2024) · Bidge Yayınları eBooks · doi:10.70269/10.70269/2124417312
Parlak, S. N., Soyleyici, N. A., ÖZSAN, M., Güler, S., & Dönmez, H. H. (2024) · Bidge Yayınları eBooks · doi:10.70269/nsacctlnu43q
First molecules to reactivate RASG12V GTPase activity
Włodarczyk, A., Tręda, C., Pacholczyk, M., Rutkowska, A., Węgierska, M., Kierasińska, A., Wasiak, K., Ciunowicz, D., Grot, D., Głowacki, P., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13580-8
Treatment options for KRAS G12C mutated metastatic colorectal cancer
Liberko, M. (2025) · Onkologie · doi:10.36290/xon.2025.008
Forster, V. R., Franco‐Liñan, M. C., Ragheb, J. R., Khatib, Z. A., & Biehler, J. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.32055
“It is also known to promote tumorigenesis through persistent signaling of the MAPK and PI3K pathway [7, 10].”
Targeting LIFR/c-Myc/DDX21 Axis to Overcome Docetaxel Resistance in Prostate Cancer
Halder, S. (2024) · DigitalCommons@UNMC
Elucidating the mechanism of NUPR1 inhibitors in pancreatic cancer treatment
Huang, C. (2021) · theses.fr (ABES) · doi:10.70675/d567c6b8z5273z4d8czba2fz1b589b04e9fe
The analysis of targeted therapies for colorectal cancer with KRAS G12C mutation
Yin, Y. (2024) · Theoretical and Natural Science · doi:10.54254/2753-8818/61/20241491
Basumatary, M., Basumatary, P., Barman, S., & Das, G. (2026) · Structural Chemistry · doi:10.1007/s11224-026-02790-w · Cited by 2
Doermann, A. S., Caspi, A., Evans, A. E., Feci, A., Entezari, A. A., Snook, A. E., & Waldman, S. A. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2026.2683096 · Cited by 1
Li, L., Li, J., Yang, L., Zhou, J., & Ma, Y. (2026) · Pharmaceuticals · doi:10.3390/ph19091388
“Mutations occur mainly at codons G12, G13, and Q61, with distinct distributions across cancer lin-https eages [12,13].”
Wang, T., Ji, C., & Zhao, T. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1967704
“Drug exposure in brain metastases, receptor resynthesis, and bypass signaling activation such as MET pathway reactivation will collectively determine its therapeutic applicability in EGFR-mutant NSCLC (35, 57).”
InfluentialHamidi, A. A., Moaven, O., Mahmoudian, R. A., & Abbaszadegan, M. R. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00849-2
“The tool was not used to generate or analyze experimental data, select studies, assign evidence levels or determine scientific properties [57–59].”
The inhibition of SOS 1-KRAS interaction by C. coggygria flavonoids through switch I/II pocket
Vitas, M. (2024) · South African Journal of Chemistry · doi:10.17159/0379-4350/2024/v78a26
Metadata
- Authors
- Lu, S., Jang, H., Nussinov, R., & Zhang, J.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Frederick National Laboratory for Cancer Research (US)
- Tel Aviv University (IL)
- Corresponding author
- Nussinov, Ruth
- Zhang, Jian
- Venue
- Scientific Reports
- Published
- 2016-02-23
- Volume
- 6
- Issue
- 1
- Pages
- 21949-21949
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4763299
- OpenAlex
- W2282990014
- Cited by
- 219
- References
- 69
- Citations by year
- 2026: 13 · 2025: 33 · 2024: 20 · 2023: 23 · 2022: 25 · 2021: 22 · 2020: 23 · 2019: 26 · 2018: 15 · 2017: 13 · 2016: 5
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services (HHSN261200800001E)
- Frederick National Laboratory for Cancer Research (HHSN261200800001E.)
- National Natural Science Foundation of China (81302698, 973 Program, HHSN261200800001E, 81473137, 2015CB910403, 81322046)
- Shanghai Rising-Star Program (13QA1402300)
- National Institutes of Health (#HHSN261200800001E, HHSN261200800001C)
- Program for New Century Excellent Talents in University (NCET-12-0355)
- National Key Research and Development Program of China (2015CB910403)
- National Cancer Institute (HHSN261200800001E))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- K-Ras4B, oncogenic Ras mutations, G12D, G12V, small GTPases, GTP hydrolysis, GDP/GTP exchange, conformational change, GTPase-activating protein, RAS-driven cancers, molecular dynamics simulation
- MeSH terms
- Amino Acid Sequence, Arginine, Glutamine, Glycine, Guanosine Diphosphate, Guanosine Triphosphate, Humans, Hydrolysis, Mutation, Neoplasm Proteins, Gene Expression, Proto-Oncogene Proteins p21(ras), Protein Structure, Secondary, Catalytic Domain, Biocatalysis, Molecular Dynamics Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.